In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.
The trial evaluated men with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease. Previous therapy with a novel hormonal therapy was allowed. The men received six intravenous injections of radium-223 every four weeks. The men’s reported pain levels were recorded throughout the trial.
In the medium follow-up period of 8.3 months, it was shown that increased pain levels were prognostic of earlier prostate cancer-related death. You can discuss this with your doctor.
OncoTargets and therapy. 2018 Dec 17 2018
Giandomenico Roviello, Rosj Gallicchio, Giovanni Bozza, Maria Grazia Rodriquenz, Michele Aieta, Giovanni Storto